ライフサイエンスコーパス: MRSA

1 MRSA acquisition and infections were not impacted by the

2 MRSA and ESBL infections accounted for the majority of t

3 MRSA bloodstream infection (BSI) incidence per 100 000 p

4 MRSA causes fulminant keratitis often requiring surgical

5 MRSA possesses an arsenal of secreted host-damaging viru

6 MRSA resistance to beta-lactam antibiotics is mediated b

7 A survey of 132 MRSA genomes assembled from long reads enabled detailed

8 solute reduction of 28.8% and avoidance of 2 MRSA-related deaths.

9 00 patients decreased between 2007 and 2016 (MRSA acquisitions, 25.4 to 4.1; and C. difficile acquisi

10 Using a test panel of 25 MRSA isolates previously associated with outbreak invest

11 al centers included 59 patients with SaB (47 MRSA, 12 MSSA) from 2015-2017.

12 The 625 MRSA isolates studied were grouped into 23 clonal comple

13 sensitive to changes in the probability of a MRSA-negative patient acquiring MRSA during their hospit

14 lts indicate little reason for concern about MRSA transmission in low-prevalence settings in the imme

15 Patients were no more likely to acquire MRSA if they were cared for using Standard Precautions v

16 Patients were no more likely to acquire MRSA if they were cared for using standard precautions v

17 ability of a MRSA-negative patient acquiring MRSA during their hospital admission.

18 he jugular-vein catheter before or 6 h after MRSA inoculation, while an equal volume of saline was ad

19 lar-vein catheter before, 6 h and 12 h after MRSA inoculation.

20 nesthetized rats when moribund or 18 h after MRSA inoculation.

21 Against MRSA, 40 mM SMG at 120 min showed a > 95% kill rate, p <

22 unique mode of action that is active against MRSA, but its clinical use is restricted to topical admi

23 ated excellent bactericidal activity against MRSA at concentrations >= 10% of honey, with vacuum-prep

24 The TZP combination lacks activity against MRSA, yet it synergized with compound 73 to kill MRSA in

25 s, are effective bactericidal agents against MRSA.

26 Screening for function against MRSA (USA300) revealed several lead hits with improved a

27 ATG16L1 is necessary for protection against MRSA strains encoding alpha-toxin(4)-a pore-forming toxi

28 s active as rifampin with vancomycin against MRSA in rat foreign body osteomyelitis, suggesting that

29 Although MRSA infections had been previously associated with high

30 Although MRSA tended to be more closely associated with healthcar

31 Among MRSA patients in the United States, median length of sta

32 We analyzed MRSA cases diagnosed in 2010 (n = 212) and 2016 (n = 214

33 S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identif

34 We identified MSSA and MRSA bacteremia using International Classification of Di

35 e models including small-colony variants and MRSA status, P aeruginosa was not independently associat

36 Anti-MRSA antimicrobial use decreased 11.3% (95% CI, -16.0% t

37 cillin-resistant Staphylococcus aureus [anti-MRSA] agents, and antipseudomonal agents) was analyzed u

38 deescalation and avoidance of empirical anti-MRSA therapy.

39 e-escalation and avoidance of empirical anti-MRSA therapy.

40 r de-escalation as well as avoidance of anti-MRSA therapy.

41 a large urban jail to determine if there are MRSA transmission networks preceding incarceration.

42 transmission of nosocomial pathogens such as MRSA.

43 Community-associated MRSA (epidemiologically defined) increased significantly

44 Community-associated MRSA is increasing among hospitalized individuals in Ont

45 s community-acquired and hospital-associated MRSA strains which are resistant to multiple drugs inclu

46 S aureus and meticillin-resistant S aureus (MRSA) can adapt to form slow-growing, antibiotic-resista

47 red in both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) strai

48 episodes of methicillin-resistant S. aureus (MRSA) bacteremia, with a rising proportion due to MSSA (

49 , including methicillin-resistant S. aureus (MRSA), has become a worldwide, major health care problem

50 -associated methicillin-resistant S. aureus (MRSA).

51 oth HKSA or methicillin-resistant S. aureus (MRSA).

52 , including methicillin resistant S. aureus (MRSA).

53 cularly for methicillin-resistant S. aureus (MRSA).

54 Conversely, methicillin-resistant S. aureus (MRSA; the drug resistant strain) is able to grow on gel

55 methicillin-resistant Staphylococcus aureus (MRSA) and a Kirschner wire (K-wire) implanted in each.

56 methicillin-resistant Staphylococcus aureus (MRSA) and bolsters the innate immune response to infecti

57 Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections declined acro

58 methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli Time-kill and transmission el

59 methicillin-resistant Staphylococcus aureus (MRSA) and other healthcare-associated infections.

60 methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa and accelerates their r

61 methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VR

62 methicillin-resistant Staphylococcus aureus (MRSA) are at high risk for infection after discharge.

63 Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with mortality of more th

64 methicillin-resistant Staphylococcus aureus (MRSA) bacteremia.

65 methicillin-resistant Staphylococcus aureus (MRSA) bacterial strain.

66 methicillin-resistant Staphylococcus aureus (MRSA) carriers.

67 methicillin-resistant Staphylococcus aureus (MRSA) causes life-threatening necrotizing pneumonia in c

68 methicillin-resistant Staphylococcus aureus (MRSA) colonization among nursing home residents is high.

69 Methicillin-resistant Staphylococcus aureus (MRSA) elimination.

70 methicillin-resistant Staphylococcus aureus (MRSA) for various infections, there are no recommendatio

71 methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin a

72 methicillin-resistant Staphylococcus aureus (MRSA) has emerged as the dominant pathogen found in bact

73 methicillin-resistant Staphylococcus aureus (MRSA) identifies unsuspected transmission events and out

74 methicillin-resistant Staphylococcus aureus (MRSA) in an environment with or without stressor by addi

75 methicillin-resistant Staphylococcus aureus (MRSA) in urban areas.

76 methicillin-resistant Staphylococcus aureus (MRSA) infection can quickly develop into severe, necroti

77 Methicillin-resistant Staphylococcus aureus (MRSA) infections cause significant mortality and morbidi

78 methicillin-resistant Staphylococcus aureus (MRSA) infections remain challenging.

79 methicillin-resistant Staphylococcus aureus (MRSA) infections.

80 Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of health care-associated infect

81 methicillin-resistant Staphylococcus aureus (MRSA) is a cornerstone of many antibiotic regimens; howe

82 methicillin-resistant Staphylococcus aureus (MRSA) is a cornerstone of many antibiotic regimens; howe

83 Methicillin resistant Staphylococcus aureus (MRSA) is a major human pathogen, which causes superficia

84 Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of ventilator-associated pne

85 Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens.

86 Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most widespread antibiotic-resistant

87 methicillin-resistant Staphylococcus aureus (MRSA) isolated from the patients' hand and room surfaces

88 methicillin-resistant Staphylococcus aureus (MRSA) isolates to determine if there are transmission ne

89 methicillin-resistant Staphylococcus aureus (MRSA) isolates.

90 methicillin-resistant Staphylococcus aureus (MRSA) persisters.

91 methicillin-resistant Staphylococcus aureus (MRSA) prevalence-not MRSA colonization-were the primary

92 methicillin-resistant Staphylococcus aureus (MRSA) remains controversial despite existing guidelines.

93 Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most common causes of health ca

94 methicillin-resistant Staphylococcus aureus (MRSA) strain epidemiology has changed since the rise of

95 methicillin-resistant Staphylococcus aureus (MRSA) strains poses a major threat to public health.

96 methicillin resistant Staphylococcus aureus (MRSA) strains.

97 methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics.

98 methicillin-resistant Staphylococcus aureus (MRSA) was inoculated into the tail vein of rats.

99 methicillin-resistant Staphylococcus aureus (MRSA)(1-3).

100 methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), extended

101 methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Pseudomo

102 methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis/faeciu

103 methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus spp. (VRE), ext

104 methicillin-resistant Staphylococcus aureus (MRSA).

105 methicillin-resistant Staphylococcus aureus (MRSA).

106 methicillin-resistant Staphylococcus aureus (MRSA).

107 ith SaB (47 methicillin-resistant S. aureus [MRSA], 12 methicillin-sensitive S. aureus [MSSA]) from 2

108 s and inhibit antibiotic-resistant bacteria (MRSA and Pseudomonas aeruginosa), the most common cause

109 Unexpectedly, however, basal MRSA clearance was also enhanced when IL-21 signaling wa

110 iable analyses, prior year SSTI and baseline MRSA colonization were associated with cumulative SSTI.

111 hicillin-resistant Staphylococcus aureus (CA-MRSA) is threatening public health as it spreads worldwi

112 hicillin-resistant Staphylococcus aureus (CA-MRSA) SSTI, their household contacts, and pets were enro

113 sociated methicillin-resistant S. aureus (CA-MRSA) strain FPR3757 (USA300).

114 hicillin-resistant Staphylococcus aureus (CA-MRSA).

115 ently labelled wild-type and mecA-deleted CA-MRSA USA400 strains across ~57,000 compounds supplemente

116 tors underlying the epidemic expansion of CA-MRSA lineages such as USA300, the predominant CA-MRSA cl

117 lineages such as USA300, the predominant CA-MRSA clone in the United States, are largely unknown.

118 mmunity-associated methicillin-resistant (CA-MRSA) S. aureus.

119 Our findings suggest that CA-MRSA success might be driven by a cell-envelope mediated

120 MRSA-[IV + fusC + tir], CC80-MRSA-IVa, CC121-MRSA-V/VT, CC152-MRSA-[V + fusC] (PVL+).

121 tir], CC80-MRSA-IVa, CC121-MRSA-V/VT, CC152-MRSA-[V + fusC] (PVL+).

122 cas + fusC + ccrA/B-1], CC8-MRSA-V/VT, CC22-MRSA-[IV + fusC + ccrAA/(C)], CC45-MRSA-[IV + fusC + tir

123 Emergence of CC398 MRSA, CC5-MRSA-IV Sri Lanka Clone and ST5/ST225-MRSA-II,

124 /VT, CC22-MRSA-[IV + fusC + ccrAA/(C)], CC45-MRSA-[IV + fusC + tir], CC80-MRSA-IVa, CC121-MRSA-V/VT,

125 identified include CC5-MRSA-V (edinA+), CC5-MRSA-[VT + fusC], CC5-MRSA-IVa (tst1+), CC5-MRSA-[V/VT +

126 5-MRSA-V (edinA+), CC5-MRSA-[VT + fusC], CC5-MRSA-IVa (tst1+), CC5-MRSA-[V/VT + cas + fusC + ccrA/B-1

127 Novel MRSA strains identified include CC5-MRSA-V (edinA+), CC5-MRSA-[VT + fusC], CC5-MRSA-IVa (tst

128 Emergence of CC398 MRSA, CC5-MRSA-IV Sri Lanka Clone and ST5/ST225-MRSA-II, Rhine-Hes

129 -MRSA-[VT + fusC], CC5-MRSA-IVa (tst1+), CC5-MRSA-[V/VT + cas + fusC + ccrA/B-1], CC8-MRSA-V/VT, CC22

130 ted and majority of CC772 strains were CC772-MRSA-V (PVL+), "Bengal- Bay Clone".

131 CC5-MRSA-[V/VT + cas + fusC + ccrA/B-1], CC8-MRSA-V/VT, CC22-MRSA-[IV + fusC + ccrAA/(C)], CC45-MRSA-

132 Variants of pandemic CC8-MRSA-[IVa + ACME I] (PVL+) USA300 were detected and majo

133 crAA/(C)], CC45-MRSA-[IV + fusC + tir], CC80-MRSA-IVa, CC121-MRSA-V/VT, CC152-MRSA-[V + fusC] (PVL+).

134 tic linezolid has been useful in controlling MRSA-related VAP infections; however clinical benefit do

135 esistance to Staphylococcus aureus, creating MRSA strains.

136 aluate whether contact precautions decreased MRSA acquisition in LTCFs, compared to standard precauti

137 ctions, but treatment failures occur despite MRSA strains being tested susceptible according to stand

138 a method to specifically capture and detect MRSA directly from patient nasal swabs with no prior cul

139 d to qualitatively and quantitatively detect MRSA, on contaminated non-absorbable surfaces.

140 -lactams in vitro and significantly enhanced MRSA eradication by oxacillin in a mouse bacteremia mode

141 oxins, produced by USA300 and other epidemic MRSA clones.

142 bly, topical auranofin completely eradicated MRSA (8-log(10) reduction) in infected PUs of obese mice

143 h probably arose locally suggest an evolving MRSA landscape.

144 We examined MRSA colonization at entrance to a large urban jail to d

145 We examined MRSA colonization upon entrance to a large urban jail to

146 oints higher in the prespecified exploratory MRSA subgroup (74.1% vs. 31.3%, difference = 42.8, 90% C

147 An extensive MRSA repertoire including CCs previously unreported in t

148 th overlap in their feeder ACHs (P < .05 for MRSA, VREfc, and CipREc), limited phylogenetic clusterin

149 peptides (adjusted odds ratio [aOR], > 2 for MRSA and VREfc/VREfm) or third-/fourth-generation cephal

150 urth-generation cephalosporins (aOR, > 2 for MRSA and VREfm).

151 than use of a nares surveillance culture for MRSA colonization, which is current clinical practice fo

152 of subsequent positive clinical culture for MRSA.

153 of subsequent positive clinical culture for MRSA.

154 n 2012 and 2017, the incidence decreased for MRSA infection (from 114.18 to 93.68 cases per 10,000 ho

155 t study of cultured HCP gloves and gowns for MRSA.

156 eated with daptomycin plus a beta-lactam for MRSA bloodstream infection had lower odds of composite c

157 that the adjunctive role of beta-lactams for MRSA in select patients helps elicit favorable host cyto

158 here are community transmission networks for MRSA that precede incarceration.

159 fairs (VA) hospitals screen each patient for MRSA nares colonization on admission and transfer.

160 015 who had surveillance tests performed for MRSA carriage.

161 rs provide clues to community reservoirs for MRSA.

162 us, to develop better clinical solutions for MRSA persistence and relapse, our modeling results indic

163 ations ($15578 vs $14792; P < .001) than for MRSA-related hospitalizations.

164 e results for MSSA were similar to those for MRSA.

165 We reconstructed transmission trees for MRSA.

166 patients treated with >= 72 hours of VAN for MRSA cSSTI from 2008-2013 at Detroit Medical Center.

167 In adults treated with VAN for MRSA cSSTI, target-AUC attainment was independently asso

168 paring rates in 2007/08 and 2015/16, was for MRSA (97%), followed by P. aeruginosa (81%), S. aureus (

169 will be needed to further reduce burden from MRSA BSIs.

170 ether, the present data reveal that EVs from MRSA play a crucial role in the survival of beta-lactam

171 The secretion of EVs from MRSA under antibiotic stressed conditions was increased

172 We investigated whether EVs from MRSA under stress condition or normal condition could de

173 Staphylococcus aureus ST45 is a major global MRSA lineage with huge strain diversity and a high clini

174 h S. aureus bacteremia, 48.5% (SE, 0.4%) had MRSA bacteremia.

175 he household environment to reduce household MRSA burden.

176 ICU MRSA and C. difficile acquisitions per 1000 patients dec

177 Most of the decline in MRSA BSIs was from decreases in USA100 BSI incidence.

178 , respectively, with a notable difference in MRSA patients (3.7% vs. 25.0%, difference = -21.3, 90% C

179 Mortality in MRSA infection was unchanged (25% group 1; 25% group 2;

180 ion between VAN AUC and clinical outcomes in MRSA cSSTIs.

181 equencing would result in a 90% reduction in MRSA acquisition, 290 new MRSA cases were avoided.

182 -0.90), suggesting that the observed rise in MRSA infections is not due to an ongoing epidemic but dr

183 vity against strains of S. aureus (including MRSA) was not affected in the presence of higher bacteri

184 Correspondingly, IL-21 induced MRSA killing by human peripheral blood neutrophils.

185 Invasive MRSA was less likely to be USA300 in patients who were o

186 We describe invasive MRSA trends by strain type.

187 illance and collecting isolates for invasive MRSA (ie, from normally sterile body sites), 2005-2013.

188 e impact of combination therapy for invasive MRSA infections.

189 e impact of combination therapy for invasive MRSA infections.Patients treated with daptomycin plus a

190 ng important for the development of invasive MRSA infections and are thus potential targets for antiv

191 , yet it synergized with compound 73 to kill MRSA in a bactericidal manner.

192 orafenib as major hit that effectively kills MRSA strains.

193 ne administered with vancomycin yielded less MRSA from bones (0.10, 3.02, and 0.10 log10 CFUs/g, resp

194 ged to major healthcare-associated lineages: MRSA (sequence type [ST] 5); VREfc (ST6); CipREc (ST131)

195 pment of an antivirulence agent for managing MRSA infections.

196 illin to reverse drug resistance in multiple MRSA strains.

197 a Panton-Valentine leucocidin (PVL)-negative MRSA isolate from patient sputum, we show that linezolid

198 a 90% reduction in MRSA acquisition, 290 new MRSA cases were avoided.

199 ehold transmission accounted for half of new MRSA acquisitions, indicating this setting as a potentia

200 In summary, CPT-nonsusceptible MRSA are dominant in clinical settings in Chile.

201 Staphylococcus aureus (MRSA) prevalence-not MRSA colonization-were the primary drivers of prescribin

202 Novel MRSA strains identified include CC5-MRSA-V (edinA+), CC5

203 Given the high NPVs, MRSA nares screening may be a powerful stewardship tool

204 Given the high NPVs, MRSA nares screening may be a powerful stewardship tool

205 Fifty-two culture-proven (52 eyes) cases of MRSA keratitis diagnosed and treated at the University o

206 Emirates (UAE), genetic characterisation of MRSA identified between December 2017 and August 2019 wa

207 lly relevant strain from the USA300 clone of MRSA, responds to avibactam by up-regulating the express

208 itro activity of CPT against a collection of MRSA isolates collected between 1999 and 2018 from nine

209 Here, we used a large dataset of MRSA sequences from multiply-sampled patients to reconst

210 To address the dynamics of MRSA persistence in the face of host immunity and typica

211 Genetically diverse, the epidemiology of MRSA is primarily characterized by the serial emergence

212 mplete sono-immunotherapeutic eradication of MRSA myositis in mice.

213 at phenotypic heterogeneity is a hallmark of MRSA persistence.

214 The hazard of MRSA infection was significantly lower in the decoloniza

215 linezolid significantly improved killing of MRSA by dysfunctional neutrophils, which was supported b

216 vivo in a clinically relevant mouse model of MRSA infection.

217 The NPV of MRSA nares screening for ruling out MRSA infection was 9

218 rmine the negative predictive value (NPV) of MRSA screening in the determination of subsequent positi

219 rmine the negative predictive value (NPV) of MRSA screening in the determinization of subsequent posi

220 ased neutrophil killing, and phagocytosis of MRSA.

221 al, transgender community were predictors of MRSA.

222 recent injection drug use were predictors of MRSA.

223 re to the LGBTQ community were predictors of MRSA.

224 recent injection drug use were predictors of MRSA. Among HIV patients, recent injection drug use, cur

225 ares swab were evaluated for the presence of MRSA.

226 The prevalence of MRSA colonization at intake was 19%.

227 Surveillance cultures assessed prevalence of MRSA colonization.

228 WGS revealed that the high prevalence of MRSA in Clinic A was not due to clonal spread in the cli

229 The rising prevalence of MRSA in the community implies more frequent introduction

230 Prevention of MRSA was a priority in a minority of participating hospi

231 ds contact precautions for the prevention of MRSA within acute care facilities, which are being used

232 In addition, a substantial proportion of MRSA infections occur after discharge from the hospital.

233 nited States, the overall unadjusted rate of MRSA acquisition was 2.6/1000 patient days.

234 g jail and potential community reservoirs of MRSA.

235 As a result of MRSA importations, an almost twofold increase in the pre

236 ine and mupirocin led to a 30% lower risk of MRSA infection than education alone.

237 ent against USA300 and additional strains of MRSA and displayed as importantly no cytotoxicity in fou

238 howed that proactive genomic surveillance of MRSA is likely to be cost-effective.

239 utic target to enhance the susceptibility of MRSA to beta-lactam antibiotics.

240 d to compare MSSA risk factors with those of MRSA.

241 educed healthcare-associated transmission of MRSA (IRR, 0.74 [95% CI, .53-1.04]; P = .08).

242 their potential utility in the treatment of MRSA infections as well as in wound healing.

243 However, neutrophil uptake of MRSA and S. pneumoniae was significantly reduced upon IF

244 lly detected both spa and SCCmec variants of MRSA and correctly identified empty-cassette strains of

245 Data on MRSA, C. difficile, vancomycin-resistant Enterococcus (V

246 e NPV of MRSA nares screening for ruling out MRSA infection was 96.5%.

247 Of the test panel MRSA genomes, 168/173 (97%) passed QC metrics based on t

248 In the per-protocol population, MRSA infection occurred in 98 of 1063 participants (9.2%

249 The sensitivity and specificity for positive MRSA clinical culture were 67.4% and 81.2%, respectively

250 Postdischarge MRSA decolonization with chlorhexidine and mupirocin led

251 improves animal survival from postinfluenza MRSA pneumonia compared with vancomycin treatment.

252 indicated that the use of routine, proactive MRSA sequencing would be associated with estimated cost

253 relatedness based on mapping to a reference MRSA genome and detection of pairwise core genome single

254 DCS resensitized MRSA to beta-lactams in vitro and significantly enhanced

255 s (SA), especially methicillin-resistant SA (MRSA), is a significant cause of morbidity and mortality

256 Vancomycin is used to treat serious MRSA infections, but treatment failures occur despite MR

257 verged with and may surpass costs of similar MRSA-related hospitalizations.

258 ng bacterial burden in a mouse model of skin MRSA infection.

259 A, CC5-MRSA-IV Sri Lanka Clone and ST5/ST225-MRSA-II, Rhine-Hesse EMRSA/New York-Japan Clone in our s

260 hus, identifying the factors that cause such MRSA persistence is of direct and urgent clinical releva

261 say and fluorescence microscopy of supported MRSA mimetic bilayers treated with oligoTEAs.

262 Engineered aptasensor targets MRSA selectively and binds to none of the other tested b

263 nce (31.3/100 000) was 1.8 times higher than MRSA (17.5/100 000).

264 The MRSA infection rate across the predischarge and 180-day

265 The MRSA population structure changed over time, with a 1.5x

266 The visual detection limit of the MRSA aptasensor swab was less than 100 CFU/ml and theore

267 %) in the decolonization group; 84.8% of the MRSA infections led to hospitalization.

268 ould consider MSSA prevention in addition to MRSA.

269 ed to a lower risk of hospitalization due to MRSA infection (hazard ratio, 0.71; 95% CI, 0.51 to 0.99

270 was based on the relative reduction in total MRSA acquisitions in a cohort of hospitalized patients i

271 d which patients are more likely to transfer MRSA to HCP and to identify which HCP interactions are m

272 dentify residents who are likely to transmit MRSA to HCWs' hands and clothing during clinical care is

273 irmatory study focused on exebacase to treat MRSA BSIs.TRIAL REGISTRATIONClinicaltrials.gov NCT031634

274 ctam-avibactam combinations have on treating MRSA infections.

275 The combination effectively treats MRSA infection, for which many antibiotics (including TZ

276 Both analysis methods identified two MRSA clusters based on relatedness, one of which contain

277 Prevention of USA300 MRSA BSIs in the community will be needed to further red

278 miology has changed since the rise of USA300 MRSA.

279 The primary outcome was MRSA or vancomycin-resistant enterococcus clinical cultu

280 The most common MDROs in NHs were MRSA (42%) and ESBL (34%); in LTACs they were VRE (55%)

281 tional study of 265 hospitalized adults with MRSA bacteremia treated with vancomycin.

282 July 2018 among 352 hospitalized adults with MRSA bacteremia.

283 Adults with MRSA BSI treated with DAP for >=72 hours and initiated <

284 s decolonization, in patients colonized with MRSA (carriers).

285 ion of individuals enter jail colonized with MRSA.

286 It was seen more commonly with MRSA, streptococcal, and pneumococcal species.

287 d improve the survival of mice infected with MRSA in vivo.

288 nofin to treat pressure ulcers infected with MRSA.

289 our rat model of bloodstream infection with MRSA.

290 High NPVs with MRSA nares screening may be used as a stewardship tool.

291 High NPVs with MRSA nares screening maybe used as a stewardship tool fo

292 Among patients with MRSA bacteremia, addition of an antistaphylococcal beta-

293 lapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial.

294 to treatment with DAP alone in patients with MRSA bloodstream infections (BSI).

295 th treatment with DAP alone in patients with MRSA bloodstream infections (BSIs).

296 improved clinical outcomes in patients with MRSA BSI.

297 Data from patients with MRSA nares screening were obtained from the VA Corporate

298 s with MSSA were more likely than those with MRSA to have no underlying medical conditions (adjusted

299 The updated Xpert MRSA/SA BC test successfully detected both spa and SCCme

300 tic variations that may interfere with Xpert MRSA/SA BC test results remain rare.